Pazopanib therapy for cerebellar hemangioblastomas in von Hippel-Lindau disease

Targeted Oncology

Volumn 7, Issue 2, 2012, Pages 145-149

  Kim, Betty Y S ^a   Jonasch, Eric ^a   McCutcheon, Ian E ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Hemangioblastoma; Pazopanib; Von Hippel Lindau disease

Indexed keywords

AMLODIPINE; MESSENGER RNA; PAZOPANIB; SUNITINIB;

ADULT; ARTICLE; ATAXIA; CASE REPORT; CRANIOTOMY; CRYOTHERAPY; DRUG RESPONSE; DRUG WITHDRAWAL; DYSARTHRIA; DYSPHAGIA; FRAMESHIFT MUTATION; GAIT DISORDER; GENE DELETION; GENETIC ANALYSIS; HETEROZYGOSITY; HISTOPATHOLOGY; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; MALE; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; STOP CODON; TUMOR VOLUME; VON HIPPEL LINDAU DISEASE;

CEREBELLAR NEOPLASMS; HEMANGIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; PYRIMIDINES; SULFONAMIDES; TREATMENT OUTCOME; VON HIPPEL-LINDAU DISEASE;

EID: 84865726638     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-012-0214-0     Document Type: Article

References (21)

1. Butman JA, Linehan WM, Lonser RR (2008) Neurologic manifestations of von Hippel-Lindau disease. JAMA 300:1334-1342
2. Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, Oldfield EH (2003) von Hippel-Lindau disease. Lancet 361:2059-2067 (Pubitemid 36695052)
3. Wanebo JE, Lonser RR, Glenn GM, Oldfield EH (2003) The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease. J Neurosurg 98(1 Suppl):82-94 (Pubitemid 36050451)
4. Hes FJ, van der Luijt RB, Lips CM (2001) Clinical management of von Hippel-Lindau (VHL) disease. Neth J Med 59:225-234 (Pubitemid 33036849)
5. Ammerman JM, Lonser RR, Dambrosia J, Butman J, Oldfield EH (2006) Long-term natural history of hemangioblastomas in von Hippel-Lindau disease: implications for treatment. Clin Neurosurg 53:324-331
6. Rogers LR, LoRusso P, Nadler P, Malik G, Shields A, Kaelin W (2011) Erlotinib therapy for central nervous system hemangioblas-tomatosis associated with von Hippel-Lindau disease: a case report. J Neuro Oncol 101:307-301
7. Niemela M, Maenpaa H, Salven P, Summanen P, Poussa K, Laatikainen L, Jaaskelainen J, Joensuu H (2001) Interferon-2a therapy in 18 hemangioblastomas. Clin Cancer Res 7:510-516
8. Madhusudan S, Deplanque G, Braybrooke JP, Cattell E, Harris AL (2004) Antiangiogenic therapy for von Hippel-Lindau disease. JAMA 291:943-944 (Pubitemid 38543750)
9. Jonasch E, McCutcheon IE, Waguespack SG, Wen S, Do KA, Davis DW, Zhang Y, Smith L, Tamboli P, Tannir NM, Gombos DS, Fuller GN and Matin SF (2011) Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. Ann Oncol, accepted
10. Gore ME, Larkin JMG (2011) Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies. Br J Cancer 104:399-406
11. Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473:298-307
12. Sanford M, Keating GM (2010) Pazopanib. BioDrugs 24:279-286
13. Friedman HS, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas Mk, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 28:4733-4740
14. Batchelor T, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK (2010) Phase II study of cediranib, an oral pan-endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 28:2817-2823
15. Iwamoto FM, Lamborn KR, Robins I, Mehta MP, Chang SM, Butowski NA, DeAngelis LM, Abrey LE, Zhang WT, Prados MD, Fine HA (2010) Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North America Brain Tumor Consortium Study 06-02). Neuro-Oncology 12:855-861
16. Bukowski RM (2010) Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma. Expert Rev Anticancer Ther 10:635-645
17. Mendel DM, Laird D, Xin X, Cherrington JM (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic phar-macodynamic relationship. Clin Cancer Res 9:327-337 (Pubitemid 36109749)
18. Kaal EC, Vecht CJ (2004) The management of brain edema in brain tumors. Curr Opin Oncol 16:593-600 (Pubitemid 39482980)
19. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58-62 (Pubitemid 40093472)
20. De Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji YJ, Conrad CA (2010) Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro-Oncology 12:233-242
21. Kumar R, Crouthamel MC, Rominger DH, Gontarek RR, Tummino PJ, Levin RA, King AG (2009) Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer 101:1717-1723